These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2009-010004-28 ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastom... not-yet-due
Trial is outside EEC, and reported results 2010-022945-52 A Phase 1 Study of BMS-354825 (Dasatinib) in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia. bad-data
Trial is outside EEC, and reported results 2010-022946-25 Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969, NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) bad-data
Ongoing 2011-003430-13 Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy) not-yet-due
Trial is outside EEC 2012-001477-82 A Children’s Oncology Group pilot study for the treatment of very high risk acute lymphoblastic leukemia in children and adolescents bad-data
Ongoing 2013-004773-27 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) not-yet-due
Other 2014-001866-90 Treatment of Patients for newly diagnoised High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine in the Very High Risk Stratum not-yet-due
Trial is outside EEC, and reported results 2016-001533-28 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults bad-data
Trial is outside EEC 2017-003444-20 A Phase 1/2 Study of CPX-351 Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML). bad-data
Ongoing 2018-004141-17 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors not-yet-due
Trial is outside EEC 2020-003468-19 ADVL0912: A PHASE 1/2 STUDY OF PF02341066, AN ORAL SMALL MOLECULE INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE (ALK) AND C-MET, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID TUMORS AND ANAPLASTIC LARGE CELL L... bad-data